Innovation under regulatory uncertainty: Evidence from medical technology

Journal of Public Economics

Volumn 145, Issue , 2017, Pages 181-200

  Stern, Ariel Dora ^a  

^a HARVARD BUSINESS SCHOOL   (United States)

Author keywords

FDA; Innovation; Medical devices; Regulation

Indexed keywords

EID: 85000702141     PISSN: 00472727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpubeco.2016.11.010     Document Type: Article

References (45)

1. Acemoglu, D., Linn, J., Market size in innovation: theory and evidence from the pharmaceutical industry. Q. J. Econ. 119:3 (2004), 1049–1090.
2. Babiarz, J.C., Pisano, D.J., Overview of FDA and drug development. Pisano, D.J., Mantus, D.S., (eds.) FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices and Biologics, 2008, Informa Healthcare USA, New York, 1–32.
3. Budish, E., Roin, B.N., Williams, H., Do firms underinvest in long-term research? Evidence from cancer clinical trials. Am. Econ. Rev. 105:7 (2015), 2044–2085.
4. Carpenter, D., Ting, M.M., Regulatory errors with endogenous agendas. Am. J. Polit. Sci. 51:4 (2007), 835–852.
5. Carpenter, D.P., Groups, the media and agency waiting costs: the political economy of FDA drug approval. Am. J. Polit. Sci., 46, 2002, 490505.
6. Carpenter, D.P., Protection without capture: product approval by a politically responsive, learning regulator. Am. Polit. Sci. Rev. 98:4 (2004), 613–631.
7. Carpenter, D.P., Power Reputation Organizational Image and Regulation at the FDA. 2010, Princeton University Press, Princeton.
8. Carpenter, D.P., Moffitt, S.I., Moore, C.D., Rynbrandt, R.T., Ting, M.M., Yohai, I., Zucker, E.J., Early entrant protection in approval regulation: theory and evidence from FDA drug review. J. Law Econ. Org. 26:3 (2010), 515–545.
9. Centers for Medicare & Medicaid Services. National Health Expenditures., 2012, Office of the Actuary, National Health Statistics Group; U.S. Department of Commerce, Bureau of Economic Analysis; and U.S. Bureau of the Census.
10. Chatterji, A.K., Spawned with a silver spoon? Entrepreneurial performance and innovation in the medical device industry. Strateg. Manag. J. 30:2 (2009), 185–206.
11. Cox, D.R., Regression Models and Life- Tables (with Discussion). J. R. Stat. Soc. B (Methodological) 34:2 (1972), 187–220.
12. DiMasi, J., Grabowski, H., R&D costs for new biotech compounds. Manag. Decis. Econ. 28 (2007), 469–479.
13. Dranove, D., Meltzer, D., Do important drugs reach the market sooner?. RAND J. Econ., 1994, 402–423.
14. Dubois, P., Mouzon, O. d., Scott Morton, F., Seabright, P., Market size and pharmaceutical innovation. RAND J. Econ. 46:4 (2015), 844–871.
15. FDA, U.S. Good Guidance Practices. 2007, US Food and Drug Administration, Rockville, MD.
16. Gabi, Generics and biosimilars initiative journal, 2012.
17. Garber, A.M., Modernizing device regulation. N. Engl. J. Med. 362:13 (2010), 1161–1163.
18. Generics and Biosimilars Initiative (GaBI). The Future of Nanomedicines — Nanosimilars. August, Available at, 2013 http://www.gabionline.net.
19. Goldman, D., Lakdawalla, D., Intellectual property, information technology, biomedical research, and marketing of patented products. Pauly, M.V., Mcguire, T.G., Barros, P.P., (eds.) Handbook of Health Economics>, vol. 2, 2011, Elsevier, New York, 825–872.
20. Grabowski, H.G., Vernon, J.M., Thomas, L.G., Estimating the effects of regulation on innovation: an international comparative analysis of the pharmaceutical industry. J. Law Econ. 21:1 (1978), 133–163.
21. Government Accountability Office. Medical Devices: FDA Should Take Steps to Ensure that High-Risk Device Types are Approved Through the Most Stringent Premarket Review Process. 2009 GAO-09-190 (January).
22. Hamburg, M.A., Innovation, regulation, and the FDA. N. Engl. J. Med. 363:23 (2010), 2228–2232.
23. Hamburg, M.A., Sharfstein, J.M., The FDA as a public health agency. N. Engl. J. Med. 360:24 (2009), 2493–2495.
24. Hellström, M., Harvey, A.R., Retinal ganglion cell gene therapy and visual system repair. Curr. Gene Ther. 11:2 (2011), 116–131.
25. Hilts, P.J., Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation. 2003, Alfred A. Knopf, New York, 23.
26. Kramer, D.B., Shuai, X. u., Kesselheim, A.S., Regulation of medical devices in the United States and European Union. N. Engl. J. Med. 366:9 (2012), 848–855.
27. Lancet, T., Approval of biosimilars in the USA — dead ringers?. Lancet, 379(9817), 2012, 686 25 February.
28. Loh, J.P., Barbash, I.M., Waksman, R., Overview of the 2011 Food and drug administration circulatory system devices panel of the medical devices advisory committee meeting on the CardioMEMS champion heart failure monitoring system. J. Am. Coll. Cardiol. 61:15 (2013), 1571–1576.
29. Maisel, W.H., Laskey, W.K., Drug-eluting stents. Circulation 115:17 (2007), e426–e427.
30. Makower, J., Meer, A., Denend, L., FDA impact on U.S. medical technology innovation: a survey of over 200 medical technology companies. 2010 November 2010.
31. Manheim, B.S., Granahan, P., Dow, K.J., ‘Follow-On Biologics’: ensuring continued innovation in the biotechnology industry. Health Aff. 25:2 (2006), 394–404.
32. Medtronic, Inc. Annual Report. Delivering Solutions, Advancing Healthcare, 2013.
33. Meier, B., Costs Surge for Medical Devices, but Benefits are Opaque. 2009, The New York Times November 5.
34. Monahan, C., Babiarz, J.C., The new drug application. Pisano, D.J., Mantus, D.S., (eds.) FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices and Biologics, 2nd, 2008, Informa Healthcare USA, New York, 69–108.
35. Munsey, R.R., Trends and events in FDA regulation of medical devices over the last fifty years. Food Drug LJ, 50, 1995, 163.
36. Olson, M., Substitution in regulatory agencies: FDA enforcement alternatives. J. Law Econ. Org. 12 (1995), 376–407.
37. Peltzman, S., Regulation of Pharmaceutical Innovation: The 1962 Amendments. American Enterprise Institute for Public Policy Research, vol. 15, 1974.
38. Redberg, R.F., Dhruva, S.S., Medical device recalls: get it right the first time: comment on medical device recalls and the FDA approval process. Arch. Intern. Med., 171(11), 2011, 1011.
39. Rovira, J., Espín, J., García, L., Olry de Labry, A., The impact of biosimilars’ entry in the EU market. Andalusian Sch. Pub. Health 30 (2011), 1–83.
40. Sall, B., FDA medical device regulation. Pisano, D.J., Mantus, D.S., (eds.) FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices and Biologics, 2nd, 2008, Informa Healthcare USA, New York, 69–108.
41. Scott Morton, F.M., Stern, A.D., Stern, S., The impact of the entry of biosimilars: evidence from Europe. Harvard Business School Working Paper No. 16-141, 2016 June.
42. Thomas, L.G., Regulation and firm size: FDA impacts on innovation. RAND J. Econ., 1990, 497–517.
43. Xu, S., Avorn, J., Kesselheim, A.S., Origins of medical innovation the case of coronary artery stents. Circ. Cardiovasc. Qual. Outcomes 5:6 (2012), 743–749.
44. Zenios, S.A., Makower, J., Yock, P.G., Biodesign: The Process of Innovating Medical Technologies. 2010, Cambridge University Press, Cambridge.
45. Zuckerman, D.M., Brown, P., Nissen, S.E., Medical device recalls and the FDA approval process. Arch. Intern. Med., 171(11), 2011, 1006.